

Supplementary 1.

Schedule for *in vivo* analysis.



Supplementary 2.


LC-HRMS Top 4-10 Compound of BJSE. (cont)




Supplementary 2.

(cont) **LC-HRMS Top 4-10 Compound of BJSE.**


D




E



F



G



Supplementary 3.


Antioxidant activity of BJSE.


Assay	Replicate 1 (ppm)	Replicate 1 (ppm)	Replicate 1 (ppm)	Mean±SEM (ppm)
DPPH	71.20	71.81	72.42	71.81±0.35
FRAP	75.80	76.30	76.80	76.30±0.29
ABTS	49.00	49.45	49.90	49.45±0.26

Supplementary 4.

Molecular docking validation.


A






- PDB ID: 1O86
- Native ligand: lisinopril (N2-[(S)-1-CARBOXY-3-PHENYLPROPYL]-L-LYSYL-L-PROLINE)
- RMSD: 1.301 A
- Binding Energy: -8.49 kcal/mol


B






- PDB ID: 1M9M
- Native ligand: 6-NITROINDAZOLE
- RMSD: 1.070 A
- Binding Energy: -3.77 kcal/mol


C






- PDB ID: 6VPF
- Native ligand: -
- RMSD: 0.813 A
- Binding Energy: −11,75 kcal/mol


D






- PDB ID: 4H3X
- Native ligand: N-2-(biphenyl-4-ylsulfonyl)-N-2-(isopropyloxy)-acetohydroxamic acid
- RMSD: 1.079 A
- Binding Energy: -8.27 kcal/mol

E





- PDB ID: 7AWC
- Native ligand: 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO) ETHOXY]PHENYL]METHYL]-(9CL)
- RMSD: 0.911 A
- Binding Energy: -9.11 kcal/mol

The Indonesian Biomedical Journal, Vol.18, No.5, October 2026, p.416-519

Print ISSN: 2085-3297, Online ISSN: 2355-9179

Supplementary 5.

Urinalysis results from all experimental groups.

Group	Mice	Urinalysis Result									
		Leukocyte	Nitrite	Urobilinogen	Ketone	Bilirubin	Glucose	Proteinuria	pH	Haematuria	Specific Gravity
Normal	**1**	-	-	0.2(3.5)	-	-	-	-	5	-	1.02
	2	-	-	0.2(3.5)	-	-	-	-	5	-	1.02
	3	-	-	0.2(3.5)	-	-	-	-	5	-	1.02
	4	-	-	0.2(3.5)	-	-	-	-	5	-	1.02
Positive	**1**	-	positive	0.2(3.5)	-	-	-	++	8	-	1.03
	2	-	positive	0.2(3.5)	-	-	-	++	8	-	1.03
	3	-	positive	0.2(3.5)	-	-	-	++	8	-	1.03
	4	-	positive	0.2(3.5)	-	-	-	++	8	-	1.03
Negative	**1**	-	-	0.2(3.5)	-	-	-	++++	8.5	-	1
	2	-	-	0.2(3.5)	-	-	-	++++	8.5	-	1
	3	-	-	0.2(3.5)	-	-	-	++++	8.5	-	1
	4	-	-	0.2(3.5)	-	-	-	++++	8.5	-	1
BJ10	**1**	-	positive	0.2(3.5)	-	-	-	+++	8.5	-	1
	2	-	positive	0.2(3.5)	-	-	-	+++	8.5	-	1
	3	-	positive	0.2(3.5)	-	-	-	+++	8.5	-	1
	4	-	positive	0.2(3.5)	-	-	-	+++	8.5	-	1
BJ20	**1**	-	positive	0.2(3.5)	-	-	-	+	8	-	1
	2	-	positive	0.2(3.5)	-	-	-	+	8	-	1
	3	-	positive	0.2(3.5)	-	-	-	+	8	-	1
	4	-	positive	0.2(3.5)	-	-	-	+	8	-	1
BJ30	**1**	-	positive	0.2(3.5)	-	-	-	+	8	-	1
	2	-	positive	0.2(3.5)	-	-	-	+	8	-	1
	3	-	positive	0.2(3.5)	-	-	-	+	8	-	1
	4	-	positive	0.2(3.5)	-	-	-	+	8	-	1

DOI: 10.18585/inabj.v18i5.4431

Supplementary 6.

Hematological profile from all experimental groups.

Groups	Mice	Hematological Assessment Result									
		RBC (10^6/µL)	HB (g/dL)	HCT (%)	Leukocyte (10^3/µL)	Lymphocyte (%)	Monocyte (%)	Neutrophil (%)	Thrombocyte (10^3/µL)	BUN (mg/dL)	Creatinine (mg/dL)
Normal	**1**	9.14	11.6	38.6	5.45	79.4	2.6	17.2	953	15.02	0.23
	2	8.31	12.1	39.3	5.74	80.1	3	19.7	1044		
	3	9.05	12.3	40.9	6.53	78.2	2.2	20.8	1100		
	4	8.71	11.4	39.5	5.84	80.5	3.3	20.1	989		
Positive	**1**	8.03	11.2	37.1	6.4	79.4	3.2	22.9	1074	17.6	0.33
	2	7.88	9.4	38.2	5	80.1	4	19.6	988		
	3	8.14	10	37.8	6.68	78.2	3.2	21.2	1145		
	4	8.05	10.1	40.3	6.9	80.5	3.6	23.1	1024		
Negative	**1**	5.88	7.9	29.4	10.6	67.7	6.8	25.7	1295	34.67	0.9
	2	5.17	7.4	27.1	11.1	66.3	6.9	28.2	1336		
	3	5.35	6.7	26	10.6	69	7	30.4	1387		
	4	4.17	6	28.2	10.6	68.6	6.5	29.3	1399		
BJ10	**1**	5.94	7.8	30.7	9.67	70.1	5.8	26.3	1264	32.2	0.78
	2	6.58	7.7	32.8	9.38	72.8	6.1	24.8	1387		
	3	5.9	6.2	31.3	8.1	74	5	27.4	1264		
	4	6.51	8.6	30.7	9.2	71.7	5.3	23.2	1289		
BJ20	**1**	8.68	8.6	34	8.86	76.6	5	23.5	1166	25.67	0.54
	2	7.35	9	33.2	7.12	73.1	4.7	25.1	1186		
	3	7.5	10.9	34.5	8.7	75	3.9	24.3	1198		
	4	7.43	10.1	36.5	7.3	74.8	4.2	22.2	1232		
BJ30	**1**	7.68	10.5	36.2	7.45	77	4.1	21.9	1038	21.45	0.4
	2	7.1	9.4	36.1	7.78	76.4	4.5	23.7	1173		
	3	8.72	10.7	37.3	7.14	77.4	4	22.4	1044		
	4	7.93	10.5	35.2	6.9	78.6	3.7	21.2	938		